Eve Health Group Limited · ASX:EVE
Eve Health — Coffee Microcaps Conference (September 2026)
18 slides from Eve Health's conference presentation, Sep 22, 2026
Slide 1: EVE Health Group: We Make Generic Drugs Better
EVE Health Group al use only ASX: EVE We Make Generic Drugs Better. 22 SEPTEMBER 2026 COFFEE MICROCAPS CONFERENCE INVESTOR PRESENTATION ASX: EVE
Slide 2: Who We Are
Who We Are WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Dedicated to improving generic drugs for patients. ◉ ✦ al use only The Company Why Reformulate? Our Skill Set An ASX-listed Australian life sciences EVE targets established medicines Formulation science, regulatory company building a commercia
Slide 3: Growth Pillars
Growth Pillars WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST The strategic pillars that make EVE’s platform commercial today. Lead Asset in Market ◎ Patient Differentiation ✦ Platform Repeatability al use only Libbo is supplied under SAS-B, Improve established medicines The nano-emulsion system appl
Slide 4: The Erectile Dysfunction Market Opportunity
The Erectile Dysfunction Market Opportunity WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST A large, growing market with high discontinuation and no established fast-onset oral alternative. 322m USD 5.3B >50% al use only Men globally affected by ED (2025) Global ED drug market size (2025) Patients who
Slide 5: Current Treatment Failures
Current Treatment Failures WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Why conventional treatments drive patient discontinuation. Drug Brand / format Generic Typical onset Patient friction Sildenafil Viagra Yes 1 hr+ Food effect / planning burden al use only Tadalafi l Cialis Yes 1 hr+ Long duration,
Slide 6: Libbo - The Solution
Libbo - The Solution WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Vardenafil oral dissolving film: a reformulated medicine built around patient convenience. ◌ What It Is ≈ How It Works al use only Vardenafil ODF: an established active Nano-emulsion solubilisation supports ingredient in a fast-dissolvi
Slide 7: One Platform. Many Compounds.
One Platform. Many Compounds. WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST A repeatable nano-emulsion process for high-value poorly soluble drugs. al use only Insoluble Nano-emulsion Oral Film or Oral Faster Onset, ◉ ▣ ϟ Molecules Solubilisation Spray Delivery Improved Bioavailability A proven comp
Slide 8: Validation Infrastructure Already Built
Validation Infrastructure Already Built WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Ahead of full product registration, the end-to-end pathway is operating today. ✓ Patient Telehealth SAS-B Pharmacy Home ◎ ◌ ▣ Education Consult Prescription Fulfilment Delivery al use only Platform › › Compliant cl
Slide 9: The Patent Cliff
The Patent Cliff WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST High-value medicines losing exclusivity create differentiated reformulation windows. Target medicine Global sales Patent expiry EVE relevance Apixaban (Eliquis) USD 12.2B 2026 Pre-BE development al use only Rivaroxaban (Xarelto) USD 6.8B
Slide 10: Accelerated Pathway
Accelerated Pathway WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST A capital-efficient route to product registration for established medicines. Conventional new-drug development: Phase I → Phase II → Phase III → 10–15 years → hundreds of millions of dollars. al use only VS Identify Apply EVE’s Product
Slide 11: Multiple Pillars, One Platform
Multiple Pillars, One Platform WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Libbo anchors the portfolio. One platform drives multiple franchises and future programs. EVE’s portfolio is structured around multiple complementary programs — all running off the same nano-emulsion platform. MEN’S HEALTH F
Slide 12: Key Milestones & Catalysts
Key Milestones & Catalysts WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Near-term value inflection points across the portfolio. Timing Milestone Detail al use only Q1 2027 BE Study Commences Libbo bioequivalence study initiated - confirming step toward full product registration. H1 2027 PE Program Up
Slide 13: Why Invest in EVE
Why Invest in EVE WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST A product-led platform with multiple paths to value creation. Product in Use ✦ IP Portfolio ◎ Vast Market ◈ Scalable Model al use only Libbo shows the platform Patents lodged to protect ED, men’s health and Capital-light. can improve de
Slide 14: Corporate Snapshot
Corporate Snapshot WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Snapshot Ownership ASX Tick er EVE Share Price (17 Sept 2026) A$0.016 15% Shares on Issue 352m 23% al use only Options on Issue 165m (4-6 cent exercise price) Mark et Capitalisation (17 Sept 2026) A$5.6m 8% Cash (30 June 2026) A$1.2m E
Slide 15: Board & Management
Board & Management WHO WE ARE WHAT WE DO HOW WE DO IT WHY INVEST Experienced leadership across pharmaceutical science, commercial execution and governance. BOARD OF DIRECTORS EXECUTIVE MANAGEMENT al use only Dr Stuart Gunzburg Ben Rohr CHIEF SCIENTIFIC OFFICER & EXECUTIVE DIRECTOR CHIEF EXECUTIVE OF
Slide 16: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation (Presentation) has been prepared by EVE Health Group Limited ABN 89 106 523 611 (EVE or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in thi
Slide 17: References
References Sources supporting the market, clinical and regulatory claims in this presentation. Previous Disclosure • “EVE to Acquire Nextract, Expanding into $5.3B Erectile Dysfunction Market”, 14 April 2025. Acquisition rationale; ED market; oral soluble-film platform; targeted ~15-minute onset; SAS
Slide 18: al use only
1/245 Churchill Ave, Subiaco WA 6008 +61 8 6465 5500 al use only info@evehealthgroup.com.au © EVE HEALTH GROUP 2026 W W W . E V E H E A L T H G R O U P . C O M . A U
EVE Health Group — Coffee Microcaps Conference (September 2026) on 6ix